Lantern Pharma Inc. SEC filings LTRN
Lantern Pharma Inc. has 262 filings in SEC EDGAR's recent list, going back to Jan 14, 2019. Its latest annual report, Form ARS, was filed on Oct 21, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 1, 2026 (listing notice). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 19, 2026 | Oct 19, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 8, 2026 | Oct 8, 2026 |
| DEF 14A | Proxy statement | Aug 8, 2025 | Aug 8, 2025 |
| PRE 14A | Preliminary proxy statement | Jul 28, 2025 | Jul 28, 2025 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Apr 27, 2023 |
| DEFA14A | Additional proxy material | May 3, 2022 | — |
| DEF 14A | Proxy statement | Apr 27, 2022 | Jun 8, 2022 |
| DEFA14A | Additional proxy material | Apr 9, 2021 | — |
| DEF 14A | Proxy statement | Apr 9, 2021 | May 19, 2021 |
Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LTRN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1763950
- Former names
- Lantern Pharma (until Jan 14, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.